5.82
3.56%
0.20
시간 외 거래:
5.82
전일 마감가:
$5.62
열려 있는:
$5.54
하루 거래량:
333.47K
Relative Volume:
0.37
시가총액:
$580.88M
수익:
-
순이익/손실:
$-299.80M
주가수익비율:
-0.4801
EPS:
-12.1221
순현금흐름:
$-217.49M
1주 성능:
-7.32%
1개월 성능:
+16.87%
6개월 성능:
+33.79%
1년 성능:
-36.25%
Acelyrin Inc Stock (SLRN) Company Profile
명칭
Acelyrin Inc
전화
805-871-4300
주소
4149 LIBERTY CANYON RD., AGOURA HILLS
Acelyrin Inc Stock (SLRN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-08-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2024-07-08 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
2023-12-13 | 개시 | Wells Fargo | Equal Weight |
2023-12-08 | 개시 | Citigroup | Neutral |
2023-09-13 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2023-09-05 | 개시 | H.C. Wainwright | Buy |
2023-05-30 | 개시 | Jefferies | Buy |
2023-05-30 | 개시 | Morgan Stanley | Overweight |
2023-05-30 | 개시 | Piper Sandler | Overweight |
2023-05-30 | 개시 | TD Cowen | Outperform |
모두보기
Acelyrin Inc 주식(SLRN)의 최신 뉴스
10 Best IPO Stocks To Buy Heading into 2025 - Insider Monkey
(SLRN) Proactive Strategies - Stock Traders Daily
Acelyrin, Inc. (NASDAQ:SLRN) Receives $11.17 Consensus PT from Analysts - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Short Interest Update - MarketBeat
The Manufacturers Life Insurance Company Acquires 4,163 Shares of Acelyrin, Inc. (NASDAQ:SLRN) - Defense World
Acelyrin (NASDAQ:SLRN) Trading Down 6.9%What's Next? - MarketBeat
(SLRN) Trading Advice - Stock Traders Daily
Acelyrin (NASDAQ:SLRN) Trading 4.8% Higher on Analyst Upgrade - MarketBeat
SLRNACELYRIN, INC. Latest Stock News & Market Updates - StockTitan
Wells Fargo & Company Boosts Acelyrin (NASDAQ:SLRN) Price Target to $15.00 - MarketBeat
ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease - The Manila Times
Did Acelyrin Inc (SLRN) perform well in the last session? - US Post News
Acelyrin (NASDAQ:SLRN) Stock Price Down 2.4%Should You Sell? - MarketBeat
Acelyrin Inc (SLRN) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Acelyrin (NASDAQ:SLRN) Shares Up 5.9%Still a Buy? - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Millennium Management LLC Has $20.47 Million Stake in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Renaissance Technologies LLC Has $1.75 Million Stake in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
160,167 Shares in Acelyrin, Inc. (NASDAQ:SLRN) Bought by Susquehanna Fundamental Investments LLC - Defense World
Susquehanna Fundamental Investments LLC Takes Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Acelyrin, Inc. (NASDAQ:SLRN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Recent Insider Activity Suggests Potential Gains for Acelyrin Inc (SLRN) - Knox Daily
Almitas Capital LLC Buys New Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Piper Sandler maintains Overweight rating on Acelyrin shares - Investing.com
Piper Sandler maintains Overweight rating on Acelyrin shares By Investing.com - Investing.com Australia
Acelyrin Inc [SLRN] Director makes an insider sale of 1 shares worth $7.0. - Knox Daily
Top investors say Acelyrin Inc (SLRN) ticks everything they need - SETE News
Acelyrin Insider Sellers Miss The Bus As Stock Jumps 12% - Simply Wall St
Can Acelyrin Inc Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle
Acelyrin (NASDAQ:SLRN) Shares Down 5.4% - MarketBeat
How did Acelyrin Inc (SLRN) fare last session? - US Post News
Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch (NASDAQ:SLRN) - Seeking Alpha
Acelyrin (NASDAQ:SLRN) Shares Gap Up to $4.60 - MarketBeat
Acelyrin stock spikes on upcoming presentation (NASDAQ:SLRN) - Seeking Alpha
Acelyrin announces positive results from Phase 3 trial of izokibep - TipRanks
ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024 - StockTitan
Acelyrin Inc (SLRN) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Acadian Asset Management LLC Makes New $590,000 Investment in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
In the Green: Acelyrin Inc (SLRN) Closes at 4.31, Up/Down -8.30 from Previous Day - The Dwinnex
Results from Acelyrin Inc (SLRN) show risk - US Post News
SLRN’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Los Angeles Capital Management LLC Takes $693,000 Position in Acelyrin, Inc. (NASDAQ:SLRN) - MarketBeat
Significant Acquisition by T. Rowe Price Investment Management in Acelyrin Inc - Yahoo Finance
Significant Acquisition by T. Rowe Price Investment Management i - GuruFocus.com
Acelyrin announces PoC data from Phase 1/2 trial of lonigutamab - TipRanks
ACELYRIN reports positive Phase 1/2 trial data for TED therapy - Investing.com Australia
Acelyrin Inc (SLRN) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of - The Bakersfield Californian
Acelyrin, Inc. (NASDAQ:SLRN) Receives $10.83 Average Target Price from Analysts - MarketBeat
How does Acelyrin Inc (SLRN) change from a tortoise to a hare? - SETE News
Is it possible to buy Acelyrin Inc(SLRN) shares at a good price now? - US Post News
Acelyrin Inc (SLRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):